Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

被引：0
|
作者：
Sullivan, Ryan
Collins, Laura
Rodrigues, Manuel
Nathan, Paul
Hassel, Jessica C.
Dummer, Reinhard
Kirkwood, John
Rutkowski, Piotr
Baurain, Jean-Francois
Butler, Marcus O.
Schlaak, Max
Ochsenreither, Sebastian
Abdullah, Shaad E.
Holland, Chris
Ranade, Koustubh
Shoushtari, Alexander N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：3
相关论文
共 50 条
  • [31] SF3B1 Mutation is Associated with Improved Long-term Survival in Metastatic Uveal Melanoma
    Ahmad, S.
    Ashwat, E.
    Wise, E. S.
    Tobin, J.
    Kammula, U. S.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S143 - S143
  • [32] Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectabl melanoma: Overall survival and response rates from REALITIVITY-047 (CA224-047)
    Long, Georgina V.
    Hodi, F. Stephen
    Lipson, Evan I.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Matamala, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
  • [33] PREDICTING OVERALL SURVIVAL (OS) BENEFIT IN PREVIOUSLY UNTREATED METASTATIC MELANOMA FROM IMPROVEMENTS IN RESPONSE OUTCOMES: A CORRELATION META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTs)
    Leung, L.
    Serafini, P.
    Srinivasan, S.
    Ejzykowicz, F.
    Pourrahmat, M. M.
    Moshyk, A.
    Kurt, M.
    VALUE IN HEALTH, 2024, 27 (06) : S46 - S46
  • [34] Induction of serum CXCL10 by tebentafusp, a gp100-CD3 bispecific fusion protein, was associated with survival in uveal melanoma in a Phase I/II Study
    Butler, Marcus
    Higgs, Brandon
    McAlpine, Cheryl
    Sacco, Joseph
    Hassel, Jessica
    Abdullah, Shaad
    Ranade, Koustubh
    Carvajal, Richard
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [35] Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Powles, Thomas
    Atkins, Michael B.
    Escudier, Bernard
    McDermott, David F.
    Alekseev, Boris Y.
    Lee, Jae-Lyun
    Suarez, Cristina
    Stroyakovskiy, Daniil
    De Giorgi, Ugo
    Donskov, Frede
    Mellado, Begona
    Banchereau, Romain
    Hamidi, Habib
    Khan, Omara
    Craine, Veronica
    Huseni, Mahrukh
    Flinn, Nick
    Dubey, Sarita
    Rini, Brian, I
    JAMA ONCOLOGY, 2022, 8 (02) : 275 - 280
  • [36] A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+patients with previously treated advanced non-uveal melanoma (TEBE-AM).
    Davar, Diwakar
    Ikeguchi, Alexandra
    Buchbinder, Elizabeth Iannotti
    Shoushtari, Alexander Noor
    Seedor, Rino S.
    Bernicker, Eric
    Weiss, Sarah A.
    Daniels, Gregory A.
    Panella, Timothy J.
    Ryan, Hannah Frances
    Goodall, Howard
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
    Koch, Elias A. T.
    Petzold, Anne
    Wessely, Anja
    Dippel, Edgar
    Eckstein, Markus
    Gesierich, Anja
    Gutzmer, Ralf
    Hassel, Jessica C.
    Knorr, Harald
    Kreuzberg, Nicole
    Leiter, Ulrike
    Loquai, Carmen
    Meier, Friedegund
    Meissner, Markus
    Mohr, Peter
    Pfoehler, Claudia
    Rahimi, Farnaz
    Schadendorf, Dirk
    Schlaak, Max
    Thoms, Kai-Martin
    Ugurel, Selma
    Utikal, Jochen
    Weichenthal, Michael
    Schuler-Thurner, Beatrice
    Berking, Carola
    Heppt, Markus V.
    FRONTIERS OF MEDICINE, 2023, 17 (05) : 878 - 888
  • [38] Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
    Elias A. T. Koch
    Anne Petzold
    Anja Wessely
    Edgar Dippel
    Markus Eckstein
    Anja Gesierich
    Ralf Gutzmer
    Jessica C. Hassel
    Harald Knorr
    Nicole Kreuzberg
    Ulrike Leiter
    Carmen Loquai
    Friedegund Meier
    Markus Meissner
    Peter Mohr
    Claudia Pföhler
    Farnaz Rahimi
    Dirk Schadendorf
    Max Schlaak
    Kai-Martin Thoms
    Selma Ugurel
    Jochen Utikal
    Michael Weichenthal
    Beatrice Schuler-Thurner
    Carola Berking
    Markus V. Heppt
    Frontiers of Medicine, 2023, 17 : 878 - 888
  • [39] Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma:results from a retrospective multicenter trial
    Elias ATKoch
    Anne Petzold
    Anja Wessely
    Edgar Dippel
    Markus Eckstein
    Anja Gesierich
    Ralf Gutzmer
    Jessica CHassel
    Harald Knorr
    Nicole Kreuzberg
    Ulrike Leiter
    Carmen Loquai
    Friedegund Meier
    Markus Meissner
    Peter Mohr
    Claudia Pfhler
    Farnaz Rahimi
    Dirk Schadendorf
    Max Schlaak
    KaiMartin Thoms
    Selma Ugurel
    Jochen Utikal
    Michael Weichenthal
    Beatrice SchulerThurner
    Carola Berking
    Markus VHeppt
    Frontiers of Medicine, 2023, 17 (05) : 878 - 888
  • [40] A BAYESIAN HIERARCHICAL MIXTURE CURE MODELLING (MCM) FRAMEWORK FOR THE JOINT UTILIZATION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN ESTIMATING LONG-TERM SURVIVORSHIP RATES IN PREVIOUSLY UNTREATED METASTATIC MELANOMA: A CASE STUDY FROM CHECKMATE-067 TRIAL
    Green, N.
    Paly, V
    Youn, J. H.
    Kurt, M.
    Moshyk, A.
    Baio, Gianluca G.
    VALUE IN HEALTH, 2022, 25 (01) : S10 - S11
12345